Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Appian Q1 2026 Earnings Call - AI Meets Process: Reliable, Mission-Critical Work Drives Strong Q1 and Raised Guidance
Appian reported a strong first quarter of 2026, with cloud subscription revenue jumping 25% year-over-year to $124.5 million and total revenue rising 21% to $202.2 million. The company exceeded its gu...
- Cloud subscription revenue grew 25% year-over-year to $124.5 million, with constant currency growth at 20%, marking the fastest growth rate in two years.
- Total revenue reached $202.2 million, up 21% year-over-year, while adjusted EBITDA came in at $26.6 million, significantly beating the $19 million to $22 million guidance range.
- Full-year 2026 guidance was raised, with cloud subscription revenue now expected to grow 18% to a midpoint of $518 million and adjusted EBITDA margin expanding to approximately 12%.
- +7 more takeaways
MasterCraft Boat Holdings Q3 2026 Earnings Call - Premium Product Momentum and MPX Merger Drive Raised Guidance
MasterCraft Boat Holdings delivered a fiscal third quarter that surpassed internal expectations, driven by disciplined execution, favorable product mix, and strong retail performance at boat shows. Ne...
- Full-year guidance raised across net sales, Adjusted EBITDA, and EPS, reflecting stronger-than-expected Q3 performance and improved retail visibility.
- Q3 net sales reached $78.2 million, up 3% year-over-year, driven by favorable model mix and pricing rather than volume growth.
- Adjusted EBITDA jumped 43% to $10.7 million, with margin expansion of 380 basis points to 13.7%, fueled by operational efficiency and lower discounting.
- +7 more takeaways
Lexicon Pharmaceuticals Q1 2026 Earnings Call - Sotagliflozin Milestones and Financial Discipline Drive H2 Catalysts
Lexicon Pharmaceuticals reported a dramatic turnaround in Q1 2026, with revenues surging to $21.1 million from $1.3 million a year earlier, driven by two $10 million milestone payments from Novo Nordi...
- Q1 2026 revenues jumped to $21.1 million from $1.3 million in Q1 2025, primarily driven by two $10 million milestone payments from Novo Nordisk for LX9851 and $1.1 million in INPEFA net sales.
- Net loss narrowed significantly to $1.0 million (less than $0.01 per share) from a $25.3 million loss in Q1 2025, reflecting reduced external R&D expenses and lower SG&A costs.
- R&D expenses fell to $12.8 million from $15.3 million year-over-year, while SG&A decreased to $9.2 million from $11.6 million, underscoring management’s commitment to operational discipline and cost control.
- +7 more takeaways
Walker & Dunlop Q1 2026 Earnings Call - Transaction Volume Surges 94% as Capital Markets Rebound
Walker & Dunlop delivered a powerful start to 2026, driven by a 94% surge in total transaction volume to $13.7 billion. Debt originations more than doubled, with agency lending up 109% and brokered de...
- Total transaction volume surged 94% to $13.7 billion, marking a sharp rebound in commercial real estate capital markets activity.
- Debt originations more than doubled year-over-year, with agency lending up 109% to $5.2 billion and brokered debt jumping 155% to $6.5 billion.
- Total revenues climbed 27% to $301 million, while diluted EPS soared 475% to $0.46, reflecting significant operating leverage as volumes recovered.
- +7 more takeaways
Orion S.A. Q1 2026 Earnings Call - Raising Full-Year Guidance Amid Geopolitical Supply Chain Shifts
Orion S.A. reported first-quarter 2026 adjusted EBITDA of $46 million, beating internal estimates on the back of a sharp demand pickup in March that has persisted through May. The company raised its f...
- 1. Q1 2026 adjusted EBITDA of $46 million exceeded internal expectations, driven by a demand surge in March that extended through May.
- 2. Full-year adjusted EBITDA guidance raised by $10 million to $170 million-$210 million, with earnings expected split roughly 50/50 between halves due to shifted European emission credit timing.
- 3. Specialty segment adjusted EBITDA grew 7% year-over-year to $27 million, supported by 3% higher volumes, favorable mix, and foreign currency tailwinds.
- +9 more takeaways
Privia Health Q1 2026 Earnings Call - EBITDA Surges 36% as Privia Consolidates Value-Based Care Market
Privia Health delivered a forceful start to 2026, posting a 36.3% year-over-year jump in adjusted EBITDA to $36.7 million and expanding its EBITDA margin to 28.5%. The company is leveraging its debt-f...
- Adjusted EBITDA surged 36.3% year-over-year to $36.7 million, with EBITDA margin expanding 290 basis points to 28.5% of care margin.
- Privia maintained full-year 2026 guidance, raising only the attributed lives range, while projecting ~20% EBITDA growth at the midpoint and 80% EBITDA-to-free-cash-flow conversion.
- Implemented providers grew 13.6% year-over-year to 5,535, and attributed lives jumped 26.5% to 1.6 million, driven by new signings and the Evolent ACO acquisition.
- +7 more takeaways
Planet Fitness Q1 2026 Earnings Call - Marketing Pivot and Price Pause Signal Growth Reset
Planet Fitness delivered a solid top-line beat in Q1 2026, with adjusted EBITDA up nearly 20% and system-wide same-club sales growth of 3.5%. But the numbers mask a growing anxiety at the membership l...
- Q1 2026 adjusted EBITDA surged 19.5% to $140 million, driven by a 22% increase in total revenue to $337 million, beating investor expectations on the bottom line.
- Net new member growth fell short at just over 700,000, missing internal targets and signaling a significant headwind for the year ahead despite adding 15 new clubs.
- Management admitted its recent marketing campaign had drifted too far toward fitness enthusiasts, causing a misalignment with the core demographic of beginners and casual gym-goers who make up the majority of the untapped market.
- +7 more takeaways
Warby Parker Inc Q1 2026 Earnings Call - AI Glasses Launch and Insurance Penetration Drive Growth
Warby Parker delivered strong Q1 2026 results, with revenue of $242.4 million, up 8.3% year-over-year, and adjusted EBITDA of $29.6 million, up 12.2% margin. Despite early-year weather disruptions and...
- Revenue reached $242.4 million, up 8.3% year-over-year, exceeding guidance despite early-year weather disruptions and the phasing out of the Home Try-On program.
- Adjusted EBITDA was $29.6 million, representing a 12.2% margin, also above guidance, with strong flow-through from revenue to profitability.
- Retail revenue grew 13.6% year-over-year, while e-commerce revenue declined 4.1% due to lapping the Home Try-On program, though underlying demand remains healthy.
- +7 more takeaways
Xeris Biopharma Q1 2026 Earnings Call - RECORLEV Nearly Doubles Revenue, Driving Raised Guidance
Xeris Biopharma delivered a strong start to 2026, with Q1 net product revenue surging 43% to $82.5 million, led by a 95% jump in RECORLEV sales. The company raised its full-year revenue guidance to $3...
- Q1 net product revenue grew 43% year-over-year to $82.5 million, outpacing prior expectations.
- RECORLEV revenue nearly doubled to $49.8 million, driven by record referrals and new patient starts.
- Full-year revenue guidance raised to $380–$390 million, reflecting confidence in sustained momentum.
- +9 more takeaways
BD Q2 Fiscal 2026 Earnings Call - Biologics Revenue Hits 55% as New CFO Vitor Roque Takes the Helm
BD delivered a solid second quarter of fiscal 2026, with revenue of $4.7 billion, up 2.6% year-over-year, and adjusted EPS of $2.90, beating expectations. The results were driven by broad-based growth...
- Revenue of $4.7 billion rose 2.6% year-over-year, with adjusted EPS of $2.90 beating expectations and full-year guidance raised to $12.52-$12.72.
- Biologics now account for 55% of Biopharma Systems revenue, driven by strong demand for GLP-1 delivery devices and new deals with major pharmaceutical companies.
- More than 90% of the portfolio delivered mid-single-digit growth, with double-digit gains in biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration.
- +7 more takeaways